# Trilogy Metals Inc.: financial statements, quarterly

TMQ · NYSE · CIK 1543418 · [Materials](/sectors/materials.md) · fiscal year ends Nov 30

Pages: [Overview](/companies/tmq.md) · [Financials](/companies/tmq/financials.md) · [Filings](/companies/tmq/filings.md) · [Insiders](/companies/tmq/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tmq/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(3.0) d](/filings/0001104659-26-015668.md) | [(3.6)](/filings/0001104659-25-095176.md) | [(1.8)](/filings/0001104659-25-095176.md) | [(1.6)](/filings/0001104659-25-095176.md) | [(1.6) d](/filings/0001104659-26-015668.md) | [(3.6)](/filings/0001104659-26-113028.md) | [(2.2)](/filings/0001104659-26-113028.md) | [(1.7)](/filings/0001104659-26-113028.md) | [(34.7) d](/filings/0001104659-26-015668.md) | [(7.1)](/filings/0001104659-26-113028.md) | [(6.3)](/filings/0001104659-26-113028.md) | [0.2](/filings/0001104659-26-113028.md) |
| Diluted EPS | $ per share | not reported | [(0.02)](/filings/0001558370-25-004293.md) | [(0.01)](/filings/0001558370-25-009156.md) | [(0.01)](/filings/0001104659-25-095176.md) | not reported | [(0.02)](/filings/0001104659-26-039216.md) | [(0.01)](/filings/0001104659-26-081550.md) | [(0.01)](/filings/0001104659-26-113028.md) | not reported | [(0.04)](/filings/0001104659-26-039216.md) | [(0.04)](/filings/0001104659-26-081550.md) | [0.00](/filings/0001104659-26-113028.md) |
| Basic EPS | $ per share | not reported | [(0.02)](/filings/0001558370-25-004293.md) | [(0.01)](/filings/0001558370-25-009156.md) | [(0.01)](/filings/0001104659-25-095176.md) | not reported | [(0.02)](/filings/0001104659-26-039216.md) | [(0.01)](/filings/0001104659-26-081550.md) | [(0.01)](/filings/0001104659-26-113028.md) | not reported | [(0.04)](/filings/0001104659-26-039216.md) | [(0.04)](/filings/0001104659-26-081550.md) | [0.00](/filings/0001104659-26-113028.md) |

- Research and development: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.6](/filings/0001558370-25-000964.md) | [2.0](/filings/0001558370-24-004639.md) | [14.0](/filings/0001558370-24-009732.md) | [25.7](/filings/0001558370-24-013186.md) | [25.8](/filings/0001104659-26-015668.md) | [25.2](/filings/0001558370-25-004293.md) | [24.6](/filings/0001558370-25-009156.md) | [23.4](/filings/0001104659-25-095176.md) | [51.6](/filings/0001104659-26-113028.md) | [47.8](/filings/0001104659-26-039216.md) | [38.8](/filings/0001104659-26-081550.md) | [31.2](/filings/0001104659-26-113028.md) |
| Current assets | $m | [2.9](/filings/0001558370-25-000964.md) | [2.2](/filings/0001558370-24-004639.md) | [14.1](/filings/0001558370-24-009732.md) | [26.1](/filings/0001558370-24-013186.md) | [26.0](/filings/0001104659-26-015668.md) | [25.3](/filings/0001558370-25-004293.md) | [24.7](/filings/0001558370-25-009156.md) | [23.7](/filings/0001104659-25-095176.md) | [51.9](/filings/0001104659-26-113028.md) | [48.0](/filings/0001104659-26-039216.md) | [39.0](/filings/0001104659-26-081550.md) | [31.6](/filings/0001104659-26-113028.md) |
| Total assets | $m | [138](/filings/0001558370-25-000964.md) | [137](/filings/0001558370-24-004639.md) | [135](/filings/0001558370-24-009732.md) | [134](/filings/0001558370-24-013186.md) | [134](/filings/0001104659-26-015668.md) | [132](/filings/0001558370-25-004293.md) | [131](/filings/0001558370-25-009156.md) | [129](/filings/0001104659-25-095176.md) | [157](/filings/0001104659-26-113028.md) | [155](/filings/0001104659-26-039216.md) | [151](/filings/0001104659-26-081550.md) | [141](/filings/0001104659-26-113028.md) |
| Current liabilities | $m | [0.5](/filings/0001558370-25-000964.md) | [0.5](/filings/0001558370-24-004639.md) | [0.5](/filings/0001558370-24-009732.md) | [0.4](/filings/0001558370-24-013186.md) | [0.8](/filings/0001104659-26-015668.md) | [0.7](/filings/0001558370-25-004293.md) | [0.9](/filings/0001558370-25-009156.md) | [0.4](/filings/0001104659-25-095176.md) | [33.1](/filings/0001104659-26-113028.md) | [33.0](/filings/0001104659-26-039216.md) | [35.2](/filings/0001104659-26-081550.md) | [23.9](/filings/0001104659-26-113028.md) |
| Total liabilities | $m | [0.5](/filings/0001558370-25-000964.md) | [0.5](/filings/0001558370-24-004639.md) | [0.5](/filings/0001558370-24-009732.md) | [0.6](/filings/0001558370-24-013186.md) | [0.9](/filings/0001104659-26-015668.md) | [0.8](/filings/0001558370-25-004293.md) | [1.0](/filings/0001558370-25-009156.md) | [0.5](/filings/0001104659-25-095176.md) | [33.2](/filings/0001104659-26-113028.md) | [33.1](/filings/0001104659-26-039216.md) | [35.3](/filings/0001104659-26-081550.md) | [23.9](/filings/0001104659-26-113028.md) |
| Shareholders' equity | $m | [138](/filings/0001104659-26-015668.md) | [136](/filings/0001104659-25-095176.md) | [135](/filings/0001104659-25-095176.md) | [134](/filings/0001104659-25-095176.md) | [133](/filings/0001104659-26-113028.md) | [132](/filings/0001104659-26-113028.md) | [130](/filings/0001104659-26-113028.md) | [129](/filings/0001104659-26-113028.md) | [124](/filings/0001104659-26-113028.md) | [121](/filings/0001104659-26-113028.md) | [116](/filings/0001104659-26-113028.md) | [117](/filings/0001104659-26-113028.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-11-30) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(459) d](/filings/0001104659-26-015668.md) | [(579)](/filings/0001558370-25-004293.md) | [(490) d](/filings/0001558370-25-009156.md) | [(785) d](/filings/0001104659-25-095176.md) | [26.0 d](/filings/0001104659-26-015668.md) | [(748)](/filings/0001104659-26-039216.md) | [(677) d](/filings/0001104659-26-081550.md) | [(1,265) d](/filings/0001104659-26-113028.md) | [(558) d](/filings/0001104659-26-015668.md) | [(2,741)](/filings/0001104659-26-039216.md) | [(1,039) d](/filings/0001104659-26-081550.md) | [(1,114) d](/filings/0001104659-26-113028.md) |
| Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-02-28) | Q2 FY2023 (2023-05-31) | Q3 FY2023 (2023-08-31) | Q1 FY2024 (2024-02-29) | Q2 FY2024 (2024-05-31) | Q3 FY2024 (2024-08-31) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [148](/filings/0001558370-24-004639.md) | [151](/filings/0001558370-24-009732.md) | [156](/filings/0001558370-24-013186.md) | [158](/filings/0001558370-25-004293.md) | [160](/filings/0001558370-25-009156.md) | [161](/filings/0001104659-25-095176.md) | [163](/filings/0001104659-26-039216.md) | [164](/filings/0001104659-26-081550.md) | [164](/filings/0001104659-26-113028.md) | [172](/filings/0001104659-26-039216.md) | [173](/filings/0001104659-26-081550.md) | [173](/filings/0001104659-26-113028.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 181,361,209 at 2026-10-02, from the cover of the [10-Q filed 2026-10-02](/filings/0001104659-26-113028.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.